We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Involvement of Lymphocyte Type B in Amyotrophic Lateral Sclerosis (ALS)

This study has been withdrawn prior to enrollment.
(Changes in the lab's focus and needs)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00846560
First Posted: February 18, 2009
Last Update Posted: October 11, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
d_yarnitsky, Rambam Health Care Campus
  Purpose
The involvement of Lymphocyte type B in Amyotrophic lateral sclerosis (ALS) patients will be compared to lymphocyte in healthy subjects.

Condition
Amyotrophic Lateral Sclerosis

Study Type: Observational
Study Design: Observational Model: Other
Time Perspective: Other
Official Title: Involvement of Lymphocyte Type B in Amyotrophic Lateral Sclerosis (ALS)

Resource links provided by NLM:


Further study details as provided by d_yarnitsky, Rambam Health Care Campus:

Enrollment: 0
Actual Study Start Date: August 2008
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts
1 ALS patients
2 Healthy subjects

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 100 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Amyotrophic lateral sclerosis and Healthy subjects
Criteria

Inclusion Criteria:

  • ALS patients who could sign ICF.

Exclusion Criteria:

  • No ALS patients age less than 18 years.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00846560


Locations
Israel
Rambam Medical center, Neurology Department
Haifa, Israel
Sponsors and Collaborators
Rambam Health Care Campus
  More Information

Responsible Party: d_yarnitsky, Head of Neurology Department, Rambam Health Care Campus
ClinicalTrials.gov Identifier: NCT00846560     History of Changes
Other Study ID Numbers: ALS04CTIL
First Submitted: February 15, 2009
First Posted: February 18, 2009
Last Update Posted: October 11, 2017
Last Verified: October 2017

Additional relevant MeSH terms:
Sclerosis
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Pathologic Processes
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases